Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Equity Ratio (2016 - 2025)

Adma Biologics (ADMA) has disclosed Equity Ratio for 14 consecutive years, with 0.76 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 7.06% year-over-year to 0.76, compared with a TTM value of 0.76 through Dec 2025, up 7.06%, and an annual FY2025 reading of 0.76, up 7.06% over the prior year.
  • Equity Ratio was 0.76 for Q4 2025 at Adma Biologics, up from 0.76 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.76 in Q4 2025 and bottomed at 0.33 in Q3 2022.
  • Average Equity Ratio over 5 years is 0.52, with a median of 0.46 recorded in 2021.
  • The sharpest move saw Equity Ratio fell 22.45% in 2022, then soared 73.89% in 2024.
  • Year by year, Equity Ratio stood at 0.51 in 2021, then dropped by 14.66% to 0.44 in 2022, then fell by 5.82% to 0.41 in 2023, then skyrocketed by 73.89% to 0.71 in 2024, then grew by 7.06% to 0.76 in 2025.
  • Business Quant data shows Equity Ratio for ADMA at 0.76 in Q4 2025, 0.76 in Q3 2025, and 0.71 in Q2 2025.